Condition: Pulmonary Arterial Hypertension · Sponsor: Apollo Therapeutics Ltd
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).
This description comes directly from the study's public registry record.
Sanjay Aggarwal, MD · 781-479-2267 · AP13@apollotx.com
Always discuss trial participation with your own doctor first.
| Hammersmith/Imperial Hospital | London, London, United Kingdom | Recruiting |
| Royal United Hospital Bath | Bath, United Kingdom | Recruiting |
| Royal Papworth Hospital | Cambridge, United Kingdom | Recruiting |
| Golden Jubilee Hospital | Clydebank, United Kingdom | Recruiting |
| Royal Brompton Hospital | London, United Kingdom | Recruiting |
| Sheffield Teaching Hospitals | Sheffield, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06846554